Recent News

• 04.15.2025 - Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
• 04.15.2025 - Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
• 04.01.2025 - Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
• 04.01.2025 - Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
• 03.25.2025 - Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
• 03.25.2025 - Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
• 03.20.2025 - Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
• 03.20.2025 - Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
• 03.03.2025 - Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
• 03.03.2025 - Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

Recent Filings

• 04.07.2025 - 8-K Current report
• 04.01.2025 - EX-99.1 EX-99.1
• 04.01.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 04.01.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.20.2025 - 8-K Current report
• 03.20.2025 - EX-99.1 EX-99.1
• 03.05.2025 - 8-K Current report
• 03.05.2025 - EX-99.1 EX-99.1
• 03.05.2025 - 425 Prospectuses and communications, business combinations